Added to YB: 2025-10-29
Pitch date: 2025-09-11
HROW [bullish]
Harrow, Inc.
-10.93%
current return
Author Info
No bio for this author
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.3B
Pitch Price
$39.44
Price Target
300.00 (+754%)
Dividend
N/A
EV/EBITDA
29.74
P/E
-253.44
EV/Sales
5.49
Sector
Pharmaceuticals
Category
growth
Harrow, Inc. - $HROW
HROW: Ophthalmic pharma targeting $1B revenue by 2027 vs current $280M (35% CAGR). VEVYE dry eye drug hit $100M 2025 run-rate, IHEEZO anesthetic $60M. Trading 15x EV/EBITDA despite 35% rev growth, 60% EBITDA growth. Price targets $120-300 based on 25x-35x multiples. Catalyst: new launches, supply expansion.
Read full article (11 min)